Effect of long-term haloperidol treatment on striatal neuropeptides: Relation to stereotyped behavior

Brain Research

Volumn 731, Issue 1-2, 1996, Pages 57-62

  Marin, Concepció ^a,b   Engber, Thomas M ^b   Bonastre, Merce ^a   Chase, Thomas N ^b   Tolosa, Eduardo ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Dynorphin; Enkephalin; Haloperidol; Somatostatin; Stereotypy; Substance P

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENKEPHALIN; HALOPERIDOL; NEUROPEPTIDE; QUINPIROLE; SOMATOSTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030603155     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00461-1     Document Type: Article

References (43)

1. [1] Angulo, J., Christoph, G., Manning, R., Burkhart, B. and Davis, L., Reduction of dopamine receptor activity differentially alters striatal neuropeptide mRNA levels, Adv. Exp. Med. Biol., 221 (1987) 385-391.
2. [2] Angulo, J., Cadet, J. and McEwen, B., Effect of typical and atypical neuroleptic treatment on protachykinin mRNA levels in the striatum of the rat, Neurosci. Lett., 113 (1990) 217-221.
3. 2 receptor antagonists decrease prosomatostatin mRNA expression in rat striatum, Neuroscience. 44 (1991) 35-44.
4. [4] Baldessarini, R.J. and Tarsy, D., Relationship of the actions of neuroleptics drugs to the pathophysiology of tardive dyskinesia, Int. Rev. Neurobiol., 21 (1974) 1-45.
5. [5] Bannon, M.J., Lee, J.M., Giraud, P., Young, A., Affolter, H.U. and Bonner, T.I., Dopamine antagonist haloperidol decreases substance P. substance K and preprotachykinin mRNA in rat striatonigral neurons. J. Biol. Chem., 261 (1986) 6640-6644.
6. [6] Beal, M.F. and Martin, J.B., Effects of neuroleptic drugs on brain somatostatin-like immunoreactivity, Neurosci. Lett., 47 (1984) 125-130.
7. [7] Burt, D.R., Creese, I. and Snyder, S.H., Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain, Science. 196 (1977) 326-328.
8. [8] Carvey, P.M., Hitri, A., Goetz, C.G., Tanner, C.M. and Klawans, H.L., Concurrent treatment with benztropine and haloperidol attenuates development of behavioral supersensitivity but not dopamine receptor proliferation, Life Sci., 42 (1988) 2207-2215.
9. [9] Carvey, P.M., Kao, L.C., Zhangt, J., Amdur, R.L., Lin, D.H., Singh, R. and Klawans, H.L., Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity, Pharmacol. Biochem. Behav., 35 (1990) 291-300.
10. 5]-enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats, Eur. J. Pharmacol., 130 (1986) 305-309.
11. [11] de Ceballos, M.L., Jenner, P. and Marsden C.D., Acute and repeated administration of sulpiride alters Met and Leu-enkephalin content of rat brain, Neurosci. Lett., 68 (1986) 322-326.
12. 3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur. J. Neurosci., 6 (1994) 1384-1387.
13. 3 receptor in the rat brain, Neuroscience, 65 (1995) 731-745.
14. [14] DiFiglia, M. and Aronin, N., Ultrastructural features of immunoreactive somatostatin neurons in the rat caudate nucleus, J. Neurosci., 2 (1982) 1267-1274.
15. 1 receptors, Biochem. Pharmacol., 32 (1983) 2921-2927.
16. [16] Gerfen, C. and Young III, W.S., Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study, Brain Res., 460 (1988) 161-167.
17. [17] Gianutsos, G., Drawbaugh, R.B., Hynes, M.D. and Lal, H., Behavioral evidence for dopaminergic supersensitivity after haloperidol, Life Sci., 14 (1974) 887-898.
18. [18] Gunne, L.M. and Haggstrom, J.A., Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia, Psychopharmacology, 81 (1983) 191-194.
19. [19] Hong, J., Yong, H. and Costa, E., Substance P content of substantia nigra after chronic treatment with antischizophrenic drugs, Neuropharmacology. 17 (1978) 83-85.
20. [20] Hong, J.S., Yang, H.Y.T., Fratta, A. and Costa, E., Rat striatal methionine-enkephalin content after chronic treatment with cataleptogenic and non cataleptogenic antischizophrenic drugs, J. Pharmacol. Exp. Ther., 205 (1978) 141-147.
21. 2 receptors resulting from chronic neuroleptic action, Clin. Neuropharmacol., Suppl. 9 (1986) 26-28.
22. [22] Klawans, H.L., The pharmacology of tardive dyskinesia, Am. J. Psychiatry, 130 (1973) 82-86.
23. [23] Li, S., Sivam, S. and Hong, J., Regulation of the concentration of dynorphin A 1-8 in the striatonigral pathway by the dopaminergic system, Brain Res., 398 (1986) 390-392.
24. [24] Lowry, O.H., Rosebrough, N.Y., Farr, A.L. and Randall, R.J., Protein measurement with the folin phenol reagent, J. Biol. Chem., 193 (1951) 265-275.
25. 2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity, Eur. J. Pharmacol., 231 (1993) 191-196.
26. 2 dopamine-mediated mechanisms and behavioral supersensitivity, Pharmacol. Biochem. Behav., 45 (1993) 195-200.
27. 2 antagonists, Neuroscience, 25 (1988) 525-532.
28. 2 interactions, Eur. J. Pharmacol., 160 (1989) 377-384.
29. [29] Palkovits, M., Isolated removal of hypothalamic or other brain nucleus of the rat, Brain Res., 59 (1973) 449-450.
30. [30] Parashos, S.A., Barone, P., Marin, C., Paraschos, A.J., Kapitzoglou-Logothetis, V. and Chase, T.N., Haloperidol and SCH23390-induced dopaminergic supersensitivities are not additive in the rat, Psychopharmacology, 98 (1989) 189-192.
31. [31] Quirion, R., Gandreau, P., Martel, J.C., St. Pierre, S. and Zamir, N., Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra, Brain Res., 331 (1985) 358-362.
32. [32] Radke, J.M., MacCennan, A.J., Vincent, S.R. and Fibigar, H.C., Comparison between short and long-term haloperidol administration on somatostatin and substance P concentrations in the rat brain, Brain Res., 445 (1988) 55-60.
33. [33] Sabol, S.L., Yoshikawa, K. and Hong, J.S., Regulation of Met-en-kephalin precursor mRNA in rat striatum by haloperidol and lithium, Biochem. Biophys. Res. Commun., 113 (1983) 391-399.
34. [34] Sant, W.W. and Ellison, G., Drug holidays alter onset of oral movements in rats following chronic haloperidol, Biol. Psychiatry, 19 (1984) 95-99.
35. [35] Schwartz, J.C., Giros, B., Martres, M.P. and Sokoloff, P., Dopamine receptor family: molecular biology and pharmacology, Semin. Neurosci., 4 (1992) 99-108.
36. 1 receptors, Life Sci. 44 (1989) 229-236.
37. [37] Sibley, D.R. and Monsma, F.J. Jr., Molecular biology of dopamine receptors, Trends Pharmacol. Sci., 13 (1992) 61-65.
38. [38] Takagi, H., Somogyi, P., Somogyi, J. and Smith,. A.D., Fine structural studies on a type of somatostatin-immunoreactive neuron and its synaptic connection in the rat neostriatum: a correlated light and electron microscopic study, J. Comp. Neurol., 214 (1983) 1-16.
39. [39] Tandon, R., Day, R., Kelsey, J.E., Watson, S.J. and Akil, H., The effect of halopendol on prodynorphin and products in the rat striatum and substantia nigra, INCR Proc. NIDA Monogr., 75 (1987) 50.
40. [40] Tang, F., Costa, E. and Schwartz, J., Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injections of haloperidol for 2-3 weeks, Proc. Natl. Acad. Sci. USA 80 (1983) 3841-3844.
41. [41] Tarsy, D. and Baldessarini, J., Behavioural supersensitivity to apomorphine following chronic treatment with drugs that interfere with the synaptic function of catecholamines, Neuropharmacology, 13 (1974) 927-940.
42. [42] Waddington, J.L., Cross, A.J., Gamble, S.J. and Bourne, R.C., Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment, Science, 220 (1983) 530-532.
43. 2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy, Neuroscience, 65 (1995) 709-730.